Published in J Clin Microbiol on March 01, 1986
Influence of six antifungal agents on the chemiluminescence response of mouse spleen cells. Antimicrob Agents Chemother (1986) 0.79
Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest (1973) 17.56
Evidence for the generation of an electronic excitation state(s) in human polymorphonuclear leukocytes and its participation in bactericidal activity. Biochem Biophys Res Commun (1972) 7.50
Mechanism of the luminol-dependent chemiluminescence of human neutrophils. J Immunol (1982) 3.11
Testing the statistical certainty of a response to increasing doses of a drug. Biometrics (1985) 2.14
Effect of antimicrobial agents on human polymorphonuclear leukocyte microbicidal function. Antimicrob Agents Chemother (1981) 1.12
Assessing laboratory evidence for neoplastic activity. Biometrics (1980) 1.11
Effect of uremia on lymphocyte transformation and chemiluminescence by spleen cells of normal and Cryptococcus neoformans-infected mice. Infect Immun (1981) 0.94
Measurement of chemiluminescence in freshly drawn human blood. II. Clinical application of zymosan-induced chemiluminescence. Klin Wochenschr (1982) 0.88
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother (1997) 5.76
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother (1997) 4.14
Decreased virulence in stable, acapsular mutants of cryptococcus neoformans. Mycopathologia (1982) 4.05
Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem (1994) 3.52
Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother (2001) 2.65
Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A (1990) 2.37
In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother (1995) 2.37
Cryptococcus neoformans serotype groups encountered in Oklahoma. Am J Epidemiol (1980) 2.26
Cryptococcus neoformans: size range of infectious particles from aerosolized soil. Infect Immun (1977) 1.62
Comparative pathogenicity of auxotrophic mutants of Candida albicans. Can J Microbiol (1984) 1.39
Serotype B/C Cryptococcus neoformans isolated from patients in nonendemic areas. J Clin Microbiol (1982) 1.19
Serotypes of Cryptococcus neoformans strains isolated in Germany. J Clin Microbiol (1981) 1.13
Distribution of Cryptococcus neoformans in a natural site. Infect Immun (1981) 1.08
An overview of macrophage-fungal interactions. Mycopathologia (1986) 1.05
In vitro effect of aqueous extract of garlic (Allium sativum) on the growth and viability of Cryptococcus neoformans. Mycologia (1978) 1.04
Immunity in cryptococcosis: an overview. Mycopathologia (1982) 1.03
In-vitro inhibitory activities of 2 new orally absorbable imidazole derivatives: BAY n 7133 and BAY 1 9139. Sabouraudia (1983) 0.99
Sphingofungins A, B, C, and D; a new family of antifungal agents. I. Fermentation, isolation, and biological activity. J Antibiot (Tokyo) (1992) 0.98
The effect of variance function estimation on nonlinear calibration inference in immunoassay data. Biometrics (1996) 0.96
In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents. Eur J Clin Microbiol (1983) 0.96
Pseudohyphal forms of Cryptococcus neoformans: decreased survival in vivo. Mycopathologia (1981) 0.96
L-657,398, a novel antifungal agent: fermentation, isolation, structural elucidation and biological properties. J Antibiot (Tokyo) (1988) 0.95
New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents. Antimicrob Agents Chemother (1996) 0.95
Virulence and antifungal susceptibility of environmental and clinical isolates of Cryptococcus neoformans from Puerto Rico. Mycopathologia (1989) 0.95
Effect of uremia on lymphocyte transformation and chemiluminescence by spleen cells of normal and Cryptococcus neoformans-infected mice. Infect Immun (1981) 0.94
Some general estimation methods for nonlinear mixed-effects models. J Biopharm Stat (1993) 0.94
Cryptococcal capsular polysaccharide clearance in nonimmune mice. Mycopathologia (1982) 0.94
Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob Agents Chemother (2006) 0.93
Fatal Beauveria bassiana infection in a captive American alligator. J Am Vet Med Assoc (1979) 0.93
L-671,329, a new antifungal agent. III. In vitro activity, toxicity and efficacy in comparison to aculeacin. J Antibiot (Tokyo) (1989) 0.92
Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase. J Biol Chem (1998) 0.91
Immunization of mice with an avirulent pseudohyphal form of Cryptococcus neoformans. Mycopathologia (1979) 0.90
Kinetics of lymphocyte transformation in mice immunized with viable avirulent forms of Cryptococcus neoformans. Infect Immun (1979) 0.89
Human mycoses and current antifungal therapy. Drug News Perspect (1998) 0.89
The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol (2000) 0.89
Arundifungin, a novel antifungal compound produced by fungi: biological activity and taxonomy of the producing organisms. Int Microbiol (2001) 0.88
Increasing usage of systemic antifungal agents. Diagn Microbiol Infect Dis (1990) 0.88
Occurrence and characterization of plasmids in field isolates of Bordetella bronchiseptica. Am J Vet Res (1982) 0.88
Application of jackknife procedures to inter-experiment comparisons of parameter estimates for the Michaelis-Menten equation. Biochem J (1981) 0.88
Ethanol-cephalosporin antibiotic interactions: an animal model for the detection of disulfiram (Antabuse)-like effects. Methods Find Exp Clin Pharmacol (1983) 0.88
Candida tropicalis infection in normal, diabetic, and neutropenic mice. J Clin Microbiol (1987) 0.87
Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC. Mycopathologia (1986) 0.86
Evaluation of experimental therapeutics in a new mouse model of Helicobacter felis utilizing 16S rRNA polymerase chain reaction for detection. Scand J Gastroenterol (1997) 0.85
Immunotoxic effects of diethylstilbestrol on host resistance: comparison with cyclophosphamide. J Leukoc Biol (1984) 0.84
A sensitive and specific PCR method to detect Helicobacter felis in a conventional mouse model. Clin Diagn Lab Immunol (1996) 0.84
Effects of bifonazole, fluconazole, itraconazole, and terbinafine on the chemiluminescence response of immune cells. J Antimicrob Chemother (1987) 0.83
Yeasts and fluconazole susceptibility in the Philippines. Mycopathologia (1999) 0.82
Isolation of saprophytic Cryptococcus neoformans from Puerto Rico: distribution and variety. Mycopathologia (1989) 0.82
Renal pathology and spleen cell chemiluminescence of mice infected with a wild-type and a low-virulence mutant of Candida albicans. Zentralbl Bakteriol Mikrobiol Hyg A (1988) 0.82
L-658,310, a new injectable cephalosporin. I. In vitro antibacterial properties. J Antibiot (Tokyo) (1989) 0.80
Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men. J Clin Endocrinol Metab (1992) 0.80
Antibacterial activity of lonchocarpol A. J Nat Prod (1998) 0.80
(Acyloxy)alkyl carbamate prodrugs of norfloxacin. J Med Chem (1991) 0.79
Influence of six antifungal agents on the chemiluminescence response of mouse spleen cells. Antimicrob Agents Chemother (1986) 0.79
Auxanographic detection of experimental murine uremia with Cryptococcus neoformans. Zentralbl Bakteriol A (1980) 0.79
Cryptococcus neoformans: a central nervous system isolate from an AIDS patient that is rhinotropic in a normal mouse model. Mycopathologia (1988) 0.78
PCR detection of colonization by Helicobacter pylori in conventional, euthymic mice based on the 16S ribosomal gene sequence. Clin Diagn Lab Immunol (1996) 0.78
Cryptococcus neoformans: in vivo protection of mice by pretreatment with pyran copolymer. Mycopathologia (1984) 0.78
Restricticin, a novel glycine-containing antifungal agent. J Antibiot (Tokyo) (1991) 0.78
Immunization of mice with stable, acapsular, yeast-like mutants of Cryptococcus neoformans. Sabouraudia (1983) 0.78
Fatal mycotic pulmonary disease of captive American alligators. Vet Pathol (1979) 0.77
Immunotoxic effects of diethylstilbestrol (DES) and cadmium chloride (CAD) on host resistance: comparison with cyclophosphamide (CPS). Prog Clin Biol Res (1984) 0.76
In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts. Mycopathologia (1984) 0.76
Effects of diethylstilbestrol and cyclophosphamide on the pathogenesis of experimental Cryptococcus neoformans infections. Sabouraudia (1984) 0.76
Antibacterial efficacy of norfloxacin, trimethoprim-sulfamethoxazole, and gentamicin in experimentally-infected normal and streptozotocin-induced diabetic mice. Methods Find Exp Clin Pharmacol (1984) 0.75
Use of chemiluminescence to evaluate the influence of antifungal agents on immune cell function. Ann N Y Acad Sci (1988) 0.75
Antagonism between cefoxitin and other beta-lactams: a new perspective. J Antimicrob Chemother (1983) 0.75
L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals. J Antibiot (Tokyo) (1989) 0.75
A new polyene with antimycotic activity produced by a streptomycete from the rhizosphere of an indoor plant. Arzneimittelforschung (1983) 0.75
Evaluation of lymphocytes' influence in luminol-dependent chemiluminescence emission of mouse spleen cells. Methods Find Exp Clin Pharmacol (1986) 0.75
Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice. J Antimicrob Chemother (1985) 0.75
Lack of cross-resistance between efrotomycin and antibacterial agents used in the therapy of human and animal infections. Methods Find Exp Clin Pharmacol (1989) 0.75
Chemiluminescence as a tool for the evaluation of antimicrobial agents: a review. Methods Find Exp Clin Pharmacol (1985) 0.75
L-656,575 (OCP-9-176): a novel oxacephem. In vitro activity against aerobic and anaerobic clinical bacterial isolates. J Antibiot (Tokyo) (1988) 0.75
L-681,572--a new antifungal agent. Isolation, characterization, and biological activity. J Antibiot (Tokyo) (1989) 0.75
Lysosomotropic agents. 7. Broad-spectrum antifungal activity of lysosomotropic detergents. J Med Chem (1987) 0.75
L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy. J Antibiot (Tokyo) (1988) 0.75
Medical mycology and current trends in antifungal chemotherapy. Drug News Perspect (1998) 0.75
In vitro effect of pH and glucose concentration on the antibacterial activity of norfloxacin in urine. Methods Find Exp Clin Pharmacol (1984) 0.75
Chemiluminescence and lymphocyte transformation of immune cells in experimental uremia. Nephron (1986) 0.75